• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Malik Rajiv

    3/10/25 6:00:25 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VTRS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Malik Rajiv

    (Last) (First) (Middle)
    1000 MYLAN BOULEVARD

    (Street)
    CANONSBURG PA 15317

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Viatris Inc [ VTRS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    03/06/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Units(1) $0 03/06/2025 A 23,660 (2) (2) Common Stock 23,660 $0 23,660 D
    Explanation of Responses:
    1. As previously disclosed on October 20, 2023, the reporting person informed Viatris Inc. ("Viatris") of his intention to retire from his executive role with Viatris effective as of April 1, 2024 and agreed to remain a member of Viatris' Board of Directors. As a non-employee director, the reporting person is eligible to participate in Viatris' non-employee director compensation program. Represents restricted stock units (RSUs) granted for such service, consistent with the grants provided to Viatris' other non-employee directors.
    2. Each RSU represents the right to receive one share of common stock of Viatris. These RSUs will vest on March 6, 2026.
    /s/ Kevin Macikowski, by power of attorney 03/10/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $VTRS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VTRS

    DatePrice TargetRatingAnalyst
    6/6/2025$10.00Neutral
    Goldman
    7/19/2024$15.00Buy
    Jefferies
    10/23/2023$13.00 → $9.00Neutral → Underperform
    BofA Securities
    6/23/2023$11.00Equal Weight → Underweight
    Barclays
    4/24/2023$11.00Overweight → Equal Weight
    Barclays
    2/17/2023$16.00 → $14.00Outperform → Market Perform
    BMO Capital Markets
    1/27/2023$13.00 → $15.00Hold → Buy
    Jefferies
    11/10/2022$9.00 → $12.00Sell → Neutral
    UBS
    More analyst ratings

    $VTRS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025

      PITTSBURGH, June 12, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) will report second quarter 2025 financial results on Thursday, August 7, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website. About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to br

      6/12/25 4:30:00 PM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions

      MR-142 Achieved Primary Endpoint of ≥15-letter (≥3-line) Gain in Mesopic Low Contrast Distance Visual Acuity in Comparison to Placebo Results Showed Patient-Reported Functional Benefit in Treating Significant Chronic Night Driving Impairment in Keratorefractive Patients With Reduced Mesopic Vision, a Condition With No Current FDA-Approved Therapies No Evidence of Tachyphylaxis Was Observed In This Study Over The 6-Week Period Study Was Conducted Under FDA Special Protocol Assessment And Fast-Track Designation PITTSBURGH, June 2, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced positive top-line results from LYNX-2, a pivotal Phase 3 trial evaluati

      6/2/25 8:00:00 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viatris Announces Launch of First Clozapine Orally Disintegrating Tablet (ODT) in Canada

      ETOBICOKE, ON, May 27, 2025 /CNW/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the launch in Canada of Gen-Clozapine orally disintegrating tablets (ODT) (12.5 mg, 25 mg, 50 mg, 100 mg and 200 mg), providing a new treatment option for treatment-resistant schizophrenia patients. This marks the first availability in Canada of an orally disintegrating tablet of clozapine, which is the only approved antipsychotic for treatment-resistant schizophrenia1. It is estimated that 25% to 30% of individuals with schizophrenia meet the criteria for treatment-resistant schizophrenia.1 Dr. Ofer Agid, Medical Head of Ambulatory Services in the Schizophrenia Division at the Cent

      5/27/25 6:59:00 AM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Smith Scott Andrew bought $536,262 worth of shares (60,000 units at $8.94), increasing direct ownership by 26% to 292,807 units (SEC Form 4)

      4 - Viatris Inc (0001792044) (Issuer)

      5/14/25 6:00:11 PM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Damelio Frank A

      4 - Viatris Inc (0001792044) (Issuer)

      5/13/25 6:06:15 PM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Severino Michael

      4 - Viatris Inc (0001792044) (Issuer)

      5/13/25 6:04:29 PM ET
      $VTRS
      Biotechnology: Pharmaceutical Preparations
      Health Care